NCT07110766

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ib Clinical Study to Evaluate the Efficacy and Safety of Small Molecule MDR-001 Tablets Administered Orally for 12 Weeks Treatment in Overweight or Obesity Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: MindRank AI Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.

Conditions

• Obesity &Amp; Overweight

Interventions

Type	Name	Description
DRUG	MDR-001	Oral administration of small molecule MDR-001 tablets
DRUG	Placebo	Administered orally placebo

Timeline

• Start date: 2025-08-09
• Primary completion: 2025-09-15
• Completion: 2025-10-30
• First posted: 2025-08-08
• Last updated: 2025-08-08

Locations

1 site across 1 country: China